Zeria Pharmaceutical Co Ltd (Zeria) manufactures and distributes pharmaceutical and consumer healthcare products. The company’s pharmaceutical product range includes drugs for the treatment of ulcerative colitis, Crohn’s disease, functional dyspepsia, gastritis and ulcers and other gastrointestinal diseases. It offers combination granules, calcium channel blockers, anti-leukopenia and iron deficiency anemia agents. Zeria also markets OTC drugs for arthralgia and lumbalgia, physical fatigue and exhaustion and soft drinks, among others. Zeria is headquartered in Chuo-Ku, Tokyo, Japan.
Headquarters
Japan
Address
10-11, Nihombashi Kobuna-Cho, Chuo-Ku, Tokyo, 103-8351
Website
www.zeria.co.jp
Telephone
81 3 36632351
No of Employees
1,729
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4559 (TYO)
Revenue (2022)
$505.2M
14.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
56.4%
(2022 vs 2021)
Market Cap*
$707.0M
Net Profit Margin (2022)
XYZ
36.2%
(2022 vs 2021)
* As of and is in US$
Zeria Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Consumer Healthcare Products | Acinon |
| Granules | Acofide |
| Calcium Channel Blockers | Asacol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
Competitor Comparison
| Key Parameters | Zeria Pharmaceutical Co Ltd | Mitsui & Co Ltd | Mochida Pharmaceutical Co Ltd | Kowa Co Ltd | Taiko Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chiyoda-Ku | Shinjuku-Ku | Sakai-Shi | Osaka-Shi |
| State/Province | Tokyo | Tokyo | Tokyo | Osaka | Osaka |
| No. of Employees | 1,729 | 46,811 | 1,529 | 7,865 | 208 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sachiaki Ibe | Chairman; Chief Executive Officer | Executive Board | - | - |
| Mitsuhiro Ibe | President; Chief Operating Officer; Director | Executive Board | - | - |
| Yuuki Okazawa | Director; Managing Executive Officer | Executive Board | - | - |
| Kenichi Suzuki | Executive Officer | Senior Management | - | - |
| Mitsuru Iwai | Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward